Drugs / GIP(3-30)NH2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06368752 | May → Dec 2023 | obesity disorder | Frederikke Koefoed-Hansen | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT05375968 Comparator | Feb 2023 → May 2027 expected | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIP[3-30]NH2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06368752 ↗ |
| Action | Inhibit | “Then the hypothesis would be that the GIP antagonist GIP(3-30)NH2 will attenuate any increase in the Y-intercept in response to oral glucose in POTS patients” NCT05375968 ↗ |
| Route | Intravenous | “The participant will receive intravenous infusion of either GIP\[3-30\]NH2 (800 pmol/kg/min) or placebo (saline)” NCT06368752 ↗ |
| Target | GIP | “GIP antagonist (GIP(3-30)NH2)” NCT05375968 ↗ |